Navegando por Autor "Passos, Thaís S."
Agora exibindo 1 - 4 de 4
- Resultados por página
- Opções de Ordenação
Artigo Beneficial effects of tamarind trypsin inhibitor in chitosan–whey protein nanoparticles on hepatic injury induced high glycemic index diet: a preclinical study(International Journal Molecular Sciences, 2021) Morais, Ana Heloneida de Araujo; Aguiar, Ana J. F. C.; Queiroz, Jaluza L. C. de; Santos, Pedro P. A.; Camillo, Christina S.; Serquiz, Alexandre C.; Costa, Izael S.; Oliveira, Gerciane S.; Gomes, Ana F. T.; Matias, Lídia L. R.; Costa, Rafael O. A.; Passos, Thaís S.; https://orcid.org/0000-0002-6460-911XSeveral studies have sought new therapies for obesity and liver diseases. This study investigated the effect of the trypsin inhibitor isolated from tamarind seeds (TTI), nanoencapsulated in chitosan and whey protein isolate (ECW), on the liver health status of the Wistar rats fed with a high glycemic index (HGLI) diet. The nanoformulations without TTI (CW) and ECW were obtained by nanoprecipitation technique, physically and chemically characterized, and then administered to the animals. The adult male Wistar rats (n = 20) were allocated to four groups: HGLI diet + water; standard diet + water; HGLI diet + ECW (12.5 mg/kg); and HGLI diet + CW (10.0 mg/kg), 1 mL per gagave, for ten days. They were evaluated using biochemical and hematological parameters, Fibrosis 4 Index for Liver Fibrosis (FIB-4), AST to Platelet Ratio Index (APRI) scores, and liver morphology. Both nanoparticles presented spherical shape, smooth surface, and nanometric size [120.7 nm (ECW) and 136.4 nm (CW)]. In animals, ECW reduced (p < 0.05) blood glucose (17%), glutamic oxalacetic transaminase (39%), and alkaline phosphatase (24%). Besides, ECW reduced (p < 0.05) APRI and FIB-4 scores and presented a better aspect of hepatic morphology. ECW promoted benefits over a liver injury caused by the HGLI dietArtigo Encapsulated peptides and proteins with an effect on satiety(Nanomaterials, 2023) Morais, Ana Heloneida de A.; Costa, Rafael O. de A.; Passos, Thaís S.; Silva, Eloyse Mikaelly de S.; Santos, Nicolle Caroline S. dos; https://orcid.org/0000-0002-6460-911XThe world scenario has undergone a nutritional transition in which some countries have left the reality of malnutrition and now face an epidemic of excess body weight. Researchers have been looking for strategies to reverse this situation. Peptides and proteins stand out as promising molecules with anti-obesity action. However, oral administration and passage through the gastrointestinal tract face numerous physiological barriers that impair their bioactive function. Encapsulation aims to protect the active substance and modify the action, one possibility of potentiating anti-obesity activity. Research with encapsulated peptides and proteins has demonstrated improved stability, delivery, controlled release, and increased bioactivity. However, it is necessary to explore how proteins and peptides affect weight loss and satiety, can impact the nutritional status of obesity, and how encapsulation can enhance the bioactive effects of these molecules. This integrative review aimed to discuss how the encapsulation of protein molecules impacts the nutritional status of obesity. From the studies selected following pre-established criteria, it was possible to infer that the encapsulation of proteins and peptides can contribute to greater efficiency in reducing weight gain, changes in adipose tissue function, and lower hormone levels that modulate appetite and body weight in animals with obesityArtigo Nanoparticles containing tamarind isolate protein potentiate the satiety without promoting the anti-Inflammatory effect in a preclinical model of diet-Induced obesity(Foods, 2022) Morais, Ana Heloneida de Araújo; Costa, Rafael O. A.; Medeiros, Isaiane; Queiroz, Jaluza L. C. de; Matias, Lídia L. R.; Lima, Mayara S. R.; Oliveira, Gerciane S. de; Aguiar, Ana Júlia F. C.; Costa, Izael S.; Silva, Eloyse Mikaelly de S.; Santos, Nicolle Caroline S. dos; Passos, Thaís S.; https://orcid.org/0000-0002-6460-911XThe study aimed to evaluate the nanoparticles (ECW) containing tamarind trypsin inhibitor (TTI) concerning the storage effect under different conditions on antitrypsin activity and the bioactive potential in a preclinical model. ECW was exposed to different pH and temperatures to evaluate the interaction between TTI and its encapsulating agents, monitored by antitrypsin activity. Wistar rats (n = 25) with obesity induced by diet were divided into groups: untreated; treatment with nutritionally adequate diet; treatment with nutritionally adequate diet and ECW/12.5 mg/kg; treatment with ECW/12.5 mg/kg; and treatment with TTI/25 mg/kg. The groups were evaluated over ten days with regards to satiety, zoometric, biochemical, and inflammatory parameters, using ten times less TTI (2.5 mg/kg) contained in ECW. TTI was protected and encapsulated in ECW without showing residual inhibitory activity. Only at gastric pH did ECW show antitrypsin activity. At different temperatures, it showed high antitrypsin activity, similar to TTI. The animals treated with ECW had significantly reduced body weight variation (p < 0.05), and only TTI treatment reduced the inflammatory parameters significantly (p < 0.05). The study showed that by using lower concentrations of TTI in ECW it was possible to perceive promising effects with perspectives of use in functional products for managing obesity and its complicationsArtigo Tamarind (Tamarindus indica L.) seed a candidate protein source with potential for combating SARS-CoV-2 infection in obesity(Drug Target Insights, 2021) Morais, Ana Heloneida de Araújo; Medeiros, Amanda F. de; Medeiros, Isaiane; Lima, Vanessa C. O. de; Luz, Anna B. S.; Maciel, Bruna L. L.; Passos, Thaís S.; https://orcid.org/0000-0002-6460-911XIntroduction: Obesity and coronavirus disease (COVID)-19 are overlapping pandemics, and one might worsen the other. Methods: This narrative review discusses one of the primary mechanisms to initiate acute respiratory distress syndrome, uncontrolled systemic inflammation in COVID-19, and presents a potential candidate for adjuvant treatment. Blocking the S protein binding to angiotensin-converting enzyme 2 (ACE-2) and the 3C-like protease (3CL pro) is an effective strategy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Results: Host proteases such as FURIN, trypsin, and transmembrane serine protease 2 (TMPRSS) act in S protein activation. Tamarind trypsin inhibitor (TTI) shows several beneficial effects on the reduction of inflammatory markers (tumor necrosis factor α [TNF-α], leptin) and biochemical parameters (fasting glycemia, triglycerides, and very low-density lipoprotein [VLDL]), in addition to improving pancreatic function and mucosal integrity in an obesity model. TTI may inhibit the action of proteases that collaborate with SARS-CoV-2 infection and the neutro phil activity characteristic of lung injury promoted by the virus. Conclusion: Thus, TTI may contribute to combating two severe overlapping problems with high cost and social complex implications, obesity and COVID-19.